Oxford BioMedica PLC
LSE:OXB

Watchlist Manager
Oxford BioMedica PLC Logo
Oxford BioMedica PLC
LSE:OXB
Watchlist
Price: 425 GBX -0.35% Market Closed
Market Cap: 450.2m GBX
Have any thoughts about
Oxford BioMedica PLC?
Write Note

Oxford BioMedica PLC
Cash & Cash Equivalents

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Oxford BioMedica PLC
Cash & Cash Equivalents Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash & Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
Oxford BioMedica PLC
LSE:OXB
Cash & Cash Equivalents
ÂŁ81.4m
CAGR 3-Years
10%
CAGR 5-Years
26%
CAGR 10-Years
18%
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
Cash & Cash Equivalents
$128m
CAGR 3-Years
161%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Exscientia PLC
NASDAQ:EXAI
Cash & Cash Equivalents
ÂŁ257.6m
CAGR 3-Years
46%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Bicycle Therapeutics PLC
NASDAQ:BCYC
Cash & Cash Equivalents
$890.9m
CAGR 3-Years
51%
CAGR 5-Years
56%
CAGR 10-Years
N/A
Immunocore Holdings PLC
NASDAQ:IMCR
Cash & Cash Equivalents
ÂŁ442.6m
CAGR 3-Years
51%
CAGR 5-Years
29%
CAGR 10-Years
N/A
Genus PLC
LSE:GNS
Cash & Cash Equivalents
ÂŁ42.5m
CAGR 3-Years
-3%
CAGR 5-Years
7%
CAGR 10-Years
6%
No Stocks Found

Oxford BioMedica PLC
Glance View

Market Cap
447.5m GBX
Industry
Biotechnology

Oxford Biomedica Plc is a biopharmaceutical company, which engages in the research and development of gene and cell therapy. The company is headquartered in Oxford, Oxfordshire. The firm and its subsidiaries have developed lentiviral vector delivery system, LentiVector platform, which the Company leverages to develop in vivo and ex vivo products both in-house and with partners. Its LentiVector delivery platform has created a portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology, central nervous system (CNS) disorders and liver diseases. The firm's product pipeline includes OXB-302, OXB-203, OXB-204 and OXB-103 and OXB-401. The firm has also developed partnership with various pharmaceutical companies to develop potential gene and cell therapy products. Its partnered products include AXO-LENTI-PD, SAR 422459 and SAR421869.

OXB Intrinsic Value
365.05 GBX
Overvaluation 14%
Intrinsic Value
Price

See Also

What is Oxford BioMedica PLC's Cash & Cash Equivalents?
Cash & Cash Equivalents
81.4m GBP

Based on the financial report for Jun 30, 2024, Oxford BioMedica PLC's Cash & Cash Equivalents amounts to 81.4m GBP.

What is Oxford BioMedica PLC's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 10Y
18%

Over the last year, the Cash & Cash Equivalents growth was -37%. The average annual Cash & Cash Equivalents growth rates for Oxford BioMedica PLC have been 10% over the past three years , 26% over the past five years , and 18% over the past ten years .

Back to Top